The Luminal-like breast cancer, featured by the overexpression of estrogen receptor (ER), is defined in immunohistochemistry (IHC)-based surrogate assay as tumors with ≥1% positive staining of ER in daily clinical practice (1–4). Here, ESR1 is linked to breast carcinoma.